Recombinant human GM-CSF in small cell lung cancer

a phase I/II study.

H. Anderson*, H. Gurney, N. Thatcher, R. Swindell, J. H. Scarffe, J. Weiner

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingConference proceeding contribution

4 Citations (Scopus)

Abstract

Seventeen patients with small cell lung cancer were entered into a dose ranging phase I-II study using rhGM-CSF (Glaxo). In the phase I study patients received 50, 150, 300 or 500 micrograms/m2 GM-CSF for 10 days by daily subcutaneous injection. Full blood counts were performed thrice weekly. After 4 days off all therapy patients then received chemotherapy with doxorubicin 50 mg/m2 i.v. bolus, day 1, ifosfamide 5 g/m2 with mesna 5 g/m2 over 24 h by continuous infusion followed by mesna 3 g/m2, and etoposide 120 mg/m2 i.v. on days 1-3. A total of six courses of chemotherapy were given. In the phase II study patients received the same dose of GM-CSF as in the phase I. GM-CSF was given 24 h after the last dose of chemotherapy for 14 days. Full blood counts were checked thrice weekly and the incidence of infections noted. Patients were randomised to receive GM-CSF with either odd or even courses of chemotherapy. The leucocyte count rose from a mean of 8.7 to 21.6 x 10(9)/l at the 50 micrograms/m2 GM-CSF dosage and from 11.4 to 39.4 x 10(9)/l at the 500 micrograms/m2 dosage during the phase I study. Phase I toxicity was: bone pain in 65% of patients, rash in 47%, fever in 24%, lethargy in 12% and diarrhoea in 12%. In the phase II study the duration of neutropenia was less during the chemotherapy courses with GM-CSF (p = 0.04) but the number of infections was similar.(ABSTRACT TRUNCATED AT 250 WORDS)

Original languageEnglish
Title of host publicationSupportive Care in Cancer Patients II
EditorsHJ SENN, A GLAUS
Place of PublicationBerlin; Heidelberg
PublisherSpringer, Springer Nature
Pages155-161
Number of pages7
Volume121
ISBN (Electronic)9783642841385
ISBN (Print)9783642841408, 3540523464
DOIs
Publication statusPublished - 1991
Externally publishedYes
Event2ND INTERNATIONAL SYMP ON SUPPORTIVE CARE IN CANCER PATIENTS / 1990 SWISS CANCER CONF - ST GALLEN, Switzerland
Duration: 1 Mar 19903 Mar 1990

Publication series

NameRECENT RESULTS IN CANCER RESEARCH
PublisherSPRINGER-VERLAG BERLIN
Volume121

Conference

Conference2ND INTERNATIONAL SYMP ON SUPPORTIVE CARE IN CANCER PATIENTS / 1990 SWISS CANCER CONF
CountrySwitzerland
CityST GALLEN
Period1/03/903/03/90

Fingerprint Dive into the research topics of 'Recombinant human GM-CSF in small cell lung cancer: a phase I/II study.'. Together they form a unique fingerprint.

Cite this